Medtronic's Liberant Thrombectomy System Achieves U.S. Commercial Debut
Medtronic
Medical Device Manufacturer
Heart Future
Recently,MedtronicAnnouncing its latest developmentLiberant Thrombectomy SystemCompleted in the United StatesFirst Commercial Application。
This commercial first case surgery was successfully performed at Mount Sinai Hospital in New York, providing a new mechanical tool for the removal of thrombus in peripheral arteriovenous systems.
Deep Vein Thrombosis(deep venous thrombosis，DVT)It is a venous reflux disorder disease caused by abnormal blood clotting in deep veins, commonly occurring in the lower limbs.
Thrombus detachment can cause pulmonary artery embolism.(pulmonary embolism，PE)，DVTAndPECollectively referred to as venous thromboembolism(venous thromboembolism，VTE), which is the manifestation of the same disease at different stages.
DVTThe main adverse consequence isPEPost-thrombotic Syndrome(post thrombotic syndrome，PTS), which can significantly affect the quality of life of patients, and even lead to death.
Thrombectomy devices can be inserted percutaneously under catheter and imaging guidance.Blood Vessel, the dedicated catheter is delivered to the lesion site, and mechanical methods such as negative pressure aspiration and rotational cutting are applied to remove the thrombus, quickly restoring blood flow through the occluded vessel.Arteriovenous`, restoring distal organ perfusion`,Rescue ischemic tissue and improve prognosis.
LiberantThe system was used this time to treat a complex case of peripheral vascular thrombosis.
According toMedtronicThe official press release introduced that this deviceDemonstrates excellent catheter deliverability and precision during operation, capable of flexibly navigating complex vascular pathways and controlling blood loss through intelligent algorithms.，Making surgery more efficient and safer.
Vascular Surgery Specialist、The Chief Surgeon This TimeAjit RaoCommented:“LiberantThrombectomy System is an effective new tool that performs well even in complex cases, capable of easily handling complicated anatomical structures and limiting blood loss through intelligent algorithms.。We can remove the thrombus burden more precisely, which means a more efficient surgery for patients, aiming to help them restore blood circulation and mobility as safely and effectively as possible.”
PeripheralChief Medical Officer of Vascular HealthJohn LairdSaid: "LiberantAiming to provide precise catheter delivery while minimizing blood loss during the thrombectomy process – two key challenges often faced in thrombectomy procedures. Additionally,LiberantAndExcipioThe compatibility of the device allows doctors to combine suction and thrombectomy techniques in particularly challenging cases.
# AboutLiberantSystem
1. Scope of Application
LiberantThrombectomy System is applicable toRemoval of Fresh, Soft Emboli or Thrombi in Peripheral Arterial and Venous SystemsIf such thrombosis is not treated in time, it may lead to local tissue ischemia and necrosis, and in severe cases, it can endanger the limb or even life.
2. System Composition
（1) Core Components
Catheter System (Catheter): Provide differentFrenchSpecifications available for selection.
Thrombectomy Device (Clotbuster）：Assist in breaking up larger blood clots to improve patency.
Catheter Dilator (Dilator): Reduce damage to the blood vessel wall during catheter advancement.
Blood Conservation Unit (BCU): Equipped with ultrasonic sensors that can respond to flow rate changes in real time and intelligently adjust suction pulses.
（2）Specifications and Flexibility
Currently available specifications include6-French（6-F）、8-French(Short, Long)And12-French（12-F）。The system covers arteries, veins, and arteriovenous access, with plansIn2026YearLaunch5-FRapid Exchange Catheter。
3. Technical Advantages
Intelligent Attraction Control:LiberantThe system innovatively adoptsUltrasonic Sensing and Intelligent Algorithm Control Technology, which can adjust the suction force according to the blood flow dynamics, providing a guarantee for reducing blood loss during surgery. This design is less common in traditional mechanical thrombectomy procedures.
Precision Operation and Catheter Flexibility:The system adoptsHybrid Woven Structure, improving the catheter's torsional responsiveness and ability to enter fine blood vessels, reducing the risk of injury and enhancing surgical efficiency.
Compatible with other devices:LiberantCompatibleContego MedicalTheExcipioThrombectomy Device(Mechanical Basket Rapid Exchange Catheter), when used in conjunction, can enhance handling capabilities in complex situations. Relevant devices have all been approved.FDAApproved, and can be used in the U.S. market.
ExcipioIt is an advanced thrombus aspiration device, manufactured byContego MedicalDevelopment. This new device combines the advantages of stent retrieval and catheter aspiration,ExcipioThe biggest feature is that its thrombectomy stent can adjust its diameter according to the size of the blood vessel, thereby achieving a snug fit with the vessel. This design allows the thrombus to be delivered to the suction catheter opening in a single operation, and then the thrombus is aspirated through the suction catheter.
ExcipioThe advantages are as follows:
Combine stents and aspiration catheters to minimize blood loss.
Doctors can control and adjust the diameter of the stent, reducing damage to the blood vessel walls.
Maintain guidewire access, avoiding multiple removals and cleanings, to accelerate the thrombectomy process.
Single treatment can be performed without the use of thrombolytics, reducing the risk of bleeding and postoperative risks.
ExcipioApplicable for the immediate, controllable, and maximum removal of soft, tissue-adherent thrombi in vessel walls within a single treatment course without the use of thrombolytic agents.
# Market Overview
In recent years, with the aggravation of aging and the accumulation of cardiovascular risk factors, the incidence of thrombus-related diseases has continued to rise, leading to a significant increase in the demand for mechanical thrombectomy devices.
The global thrombectomy devices market is in a phase of steady growth and is poised to exhibit strong expansion over the next decade.
According toPrecedence ResearchIn2025Year10Month24Data released on the day,Global Thrombectomy Devices Market SizeIn2024Year estimated as16.4Billion US dollars，It is expected to start from2025Year's17.6Billion US dollarsGrowth to2034Year's32.9Billion US dollars, in2025—2034Achieved during the year7.21%Compound Annual Growth Rate (CAGR）。
Among them, the North American region occupies the industryLargest Share, China and the Asia-Pacific MarketFastest Growth。
（1) North America: The current largest market (34% share in 2024)
In 2024, North America accounted for 34% of the global market share, making it the largest market in the world.
This dominant position is mainly due to:
Mature medical infrastructure;
A rapid increase in demand for minimally invasive surgery;
The high incidence of thrombus-related diseases such as cardiovascular diseases and stroke;
FDA's Regulatory Support for Three Types of Mechanical Thrombectomy Devices (Stent Retriever in 2012, Coil Retriever in 2004, and Aspiration Device in 2008);
Leading enterprises (Medtronic, Stryker, etc.) continuous technological iteration.
Among them,United StatesThe market is particularly prominent:
U.S. Market Size:$480 million in 2025 → $920 million in 2034
CAGR：7.41%
The United States continues to solidify its global leadership with a well-established emergency medical system, multi-center clinical networks, and a rapidly increasing volume of interventional procedures.
（2) Asia-Pacific: The Fastest Growing Region in the Future
The Asia-Pacific region is expected to beThe Fastest Growing Market from 2025 to 2034.
Growth drivers include:
Enhancement of early screening capabilities;
Acceleration of Medical System Construction;
Popularization of Minimally Invasive Intervention Technology;
The scale of the elderly population is rapidly expanding;
Development of thrombectomy devices made in China accelerates.
ChinaIt stands out particularly in this area:
The burden of cardiovascular and cerebrovascular diseases continues to increase (e.g., ischemic stroke, deep vein thrombosis, peripheral artery disease);
The Growth of Thrombectomy Surgeries Driven by Medical Insurance Coverage and Healthcare Modernization Upgrades;
Local enterprises have made rapid progress in the technological iteration of catheters, aspiration systems, and stent retrievers.
GCC2025
Full Disease Solution for Cardiovascular Devices
Statement
Content Declaration:"Future of the Heart" tracks global medical technology advancements, aiming to disseminate technical and industry knowledge. All content is intended for professional exchange and academic discussion only, and does not constitute medical advice or commercial promotion. Information regarding companies, products, and registration mentioned in the text is sourced from publicly available materials or verified channels. If there are any errors or omissions, please contact us for corrections. Email: jacky@suribot.com
Copyright Statement:The original article "Heart of the Future" is owned by Beijing Siyu Bot Technology Co., Ltd. Unauthorized reproduction, excerpting, or mirroring on other websites, official accounts, or commercial platforms is prohibited; for authorized reproduction, please contact the backend to obtain permission. This platform reserves the right to pursue legal responsibilities for unauthorized full-text reproduction, rewriting, or paraphrasing.
